Ann: Unmarketable Parcels Sale Facility Update, page-8

First 8 Last

Share
Profile

Follow
TLS351

77 Posts.

9

22/04/24

16:01

Post #: 73460144
Share

Originally posted by jdpc35: ↑

I read your post and emphasis on debt reduction and I am not really sure what you are referring to.

BOL essentially has 2 types of debt on its balance sheet:

1. Lease debt that is directly tied to equipment finance (i.e their mobile cranes). They have about $58.6m of amortising lease debt to finance $72.6m of "Right of Use" assets. These leases have terms of between 1 to 5 years and are amortising at about $25m annually (in effect the depreciation expense of these right-of-use assets). The facility turns over as they sell old gear and replace with new gear - in the December half they amortised $14.6m (so reduced the debt by that amount) and bought $21.4m of new equipment.

I view this facility as "good" debt - clearly tied to the financing of depreciating assets, but not overly leveraged on the total portfolio of plant and equipment - on top of the Right of Use assets, they have a further $82.7m of unencumbered plant and equipment.

2. Balance sheet debt. This they have been amortising and we have seen it reduce from $9.4m to $7.3m on a net debt basis over the past 6 months. It was as high as $24m a couple of years ago, so they have been nicely reducing this. However, the current $7.3m net debt liability is not large relative to their annualised EBITDA (ex right-of-use depreciation so we are not double counting) which is running at circa $26m annually - in effect, they could pay off the residual of that debt within about 4 months if they absolutely had to (excluding working capital movements and capex).

So on any measure, I believe that BOL does not have a debt problem (unlike where it was about 6 years ago) and has a P&L that is sound and trending strongly in the right direction. Its current total liabilities are very sound relative to generated cash flows, are within their targets and are appropriate for an equipment heavy company.

Expand

I agree that we don't have to worry about the debt on the gear, that is fine.

But I think that balance sheet debt that is floating between 7m and 9m is receivables financing from memory. I would like to see them build up a cash buffer and move away from using factoring for working capital. There would be nothing wrong with having 10m in cash and no receivables finance.

Last edited by TLS351: 22/04/24

BOL Price at posting: 13.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

OJC

SPC to merge with Original Juice Co and Nature One Dairy

COB

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

There are more pages in this discussion • 1 more message in this thread...

First 8 Last

Add BOL (ASX) to my watchlist

(20min delay)
Last 14.0¢		Change 0.000(0.00%)		Mkt cap ! $59.74M

Open	High	Low	Value	Volume
0.0¢	0.0¢	0.0¢	$0	0

Buyers (Bids)

No.	Vol.	Price($)
4	492541	14.0¢

Sellers (Offers)

Price($)	Vol.	No.
14.5¢	1426597	8

View Market Depth

No.	Vol.	Price($)
4	492541	0.140
8	1048776	0.135
7	188811	0.130
2	206000	0.125
2	8340	0.120

Price($)	Vol.	No.
0.145	1426597	8
0.150	656017	5
0.155	75000	1
0.160	527611	4
0.165	5715	1

Last trade - 16.12pm 02/10/2024 (20 minute delay)

BOL (ASX) Chart

Day chart unavailable

Ann: Unmarketable Parcels Sale Facility Update, page-8

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: Unmarketable Parcels Sale Facility Update, page-8

Top Stories

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

SPC to merge with Original Juice Co and Nature One Dairy

Cobalt Blue sees A$60M price tag for Kwinana, WA refinery – but $68M value for stage one

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News